LinusBio Launches ClearStrand-ASD Autism Screening Test in Japan

LinusBio’s ClearStrand-ASD has Entered Japan

Announcement

LinusBio, a popular player in precision exposome medicine, proudly declared that Clearstrand-ASD, its biochemical autism screening test, is available in Japan for research purposes via a partnership with YAC bio. This successful step marks Linusbio’s first-ever international reach and shows a prominent step in the company’s mission to provide earlier identification of autism spectrum disorder (ASD) worldwide.

The Clearstrand-ASD needs only a strand of hair to address molecular signatures connected with autism spectrum disorder. This non-invasive, creative approach enables healthcare providers with an objective screening method. This will support identification of a certain ASD risk early as one month of age, permitting families to get follow-up or involvement details during the most critical period of early development. This international expansion will strengthen recognition.

LinusBio’s Expansion Journey

The Japanese launch stands on a clearstrand-ASD’s successful marketing across the United States, which has now entered 49 states. YAC bio will collaborate with hospital systems in Japan to provide the execution of this biomarker test for autism. The linusbio’s reach in Japan has been possible with its existing partnership with YAC bio, a part of YAC holdings, the Japanese multinational that invested around 1 billion yen in the company. Apart from market access, YAC Holdings supported automation potency and manufacturing expertise for Linusbio’s scaling. LinusBio is behind evaluating additional markets where Clearstrand-ASD can meet the required attention to early autism identification.

Views and Statements from Company Leaders

Founder and CEO of LinusBio, Dr. Manish Arora, said, “Today is a changing moment in our mission to create early autism screening accessible globally. Japan shows re first step crossing our borders, and we selected this market because of its systematic healthcare infrastructure and promising pediatric developmental care. The Japanese families facing autism will now have access to the same robust screening technology that has already helped various American families with quick answers.”

President and CEO, YAC Holdings co, Ltd., Takefumi Momose said, “By merging the world’s first-ever hair-cutting robotics technology with the creative hair exposome analysis fueled by LinusBio in the United States, we have contributed to the development of the world’s first-ever biomarker screening test for autism spectrum disorder. With the launch in the US, we are now offering this test in Japan via our partner company, YAC bio. We kindly hope to reach and support families, individuals, and communities with the test in Japan who are worried about autism.”